Straits Times Index
3,298.53 -15.52 (-0.47%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,204.66 -431.56 (-2.20%) FTSE 100
8,424.20 0.00 (0.00%) Bitcoin USD
71,147.56 +4,616.05 (+6.94%) CMC Crypto 200
1,531.51 +42.97 (+2.89%)
HCM May 2024 12.500 call
| Previous close | 5.60 |
| Open | 5.60 |
| Bid | 8.40 |
| Ask | 11.60 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 5.60 - 5.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireHUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, lead
- GlobeNewswire
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 202
- GlobeNewswire
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui’s camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phas
